Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells

Jun An, Ying Xue, Meijun Long, Ge Zhang, Junhang Zhang, Hang Su

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cancer killer in the world. Despite the recent advances in its diagnosis and therapy, the prognosis of NSCLC patients remains very poor, mainly due to the development of drug resistance and metastasis. Both the chemokine network and the matrix metalloproteinase (MMP) system play important roles in cancer cell metastasis. The disruption of CCL2/CCR2 chemokine signaling has been shown to suppress cancer cellviability and metastasis. CCL2-neutralizing antibodies, which have shown promising therapeutic efficacy in several cancer models, are not widely used due to technical issues. CCR2 antagonism has thus become an alternative method for cancer treatment. However, the effect of CCR2 antagonists on NSCLC progression remains poorly understood. Here, we investigated the effect of CCR2 antagonist (CAS445479-97-0) on the proliferation, migration and invasion of human lung adenocarcinoma A549 cells by using WST-1 cell viability assay, transwell migration assay, wound healing scratch assay and Matrigel invasion assay. We demonstrated that CCL2 treatment promoted A549 cell viability, motility and invasion by upregulating MMP-9 expression and that this induction was significantly suppressed by CAS 445479-97-0. Taken together, our data suggested that the CCR2 antagonist would be a potential drug for treating CCR2-positive NSCLC patients.

Original languageEnglish (US)
Pages (from-to)39230-39240
Number of pages11
JournalOncotarget
Volume8
Issue number24
DOIs
StatePublished - 2017

Fingerprint

Matrix Metalloproteinase 9
Non-Small Cell Lung Carcinoma
Down-Regulation
Neoplasms
Neoplasm Metastasis
Cell Survival
Chemokine CCL2
Therapeutics
Neutralizing Antibodies
Matrix Metalloproteinases
Chemokines
Drug Resistance
Wound Healing
Cell Movement
Lung Neoplasms
Pharmaceutical Preparations
A549 Cells

Keywords

  • CCR2 antagonist
  • MMP-9
  • Motility and invasion
  • Non-small cell lung cancer
  • Viability

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. / An, Jun; Xue, Ying; Long, Meijun; Zhang, Ge; Zhang, Junhang; Su, Hang.

In: Oncotarget, Vol. 8, No. 24, 2017, p. 39230-39240.

Research output: Contribution to journalArticle

An, Jun ; Xue, Ying ; Long, Meijun ; Zhang, Ge ; Zhang, Junhang ; Su, Hang. / Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. In: Oncotarget. 2017 ; Vol. 8, No. 24. pp. 39230-39240.
@article{fa57cda06ee046a3ad0887530ff32214,
title = "Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells",
abstract = "Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cancer killer in the world. Despite the recent advances in its diagnosis and therapy, the prognosis of NSCLC patients remains very poor, mainly due to the development of drug resistance and metastasis. Both the chemokine network and the matrix metalloproteinase (MMP) system play important roles in cancer cell metastasis. The disruption of CCL2/CCR2 chemokine signaling has been shown to suppress cancer cellviability and metastasis. CCL2-neutralizing antibodies, which have shown promising therapeutic efficacy in several cancer models, are not widely used due to technical issues. CCR2 antagonism has thus become an alternative method for cancer treatment. However, the effect of CCR2 antagonists on NSCLC progression remains poorly understood. Here, we investigated the effect of CCR2 antagonist (CAS445479-97-0) on the proliferation, migration and invasion of human lung adenocarcinoma A549 cells by using WST-1 cell viability assay, transwell migration assay, wound healing scratch assay and Matrigel invasion assay. We demonstrated that CCL2 treatment promoted A549 cell viability, motility and invasion by upregulating MMP-9 expression and that this induction was significantly suppressed by CAS 445479-97-0. Taken together, our data suggested that the CCR2 antagonist would be a potential drug for treating CCR2-positive NSCLC patients.",
keywords = "CCR2 antagonist, MMP-9, Motility and invasion, Non-small cell lung cancer, Viability",
author = "Jun An and Ying Xue and Meijun Long and Ge Zhang and Junhang Zhang and Hang Su",
year = "2017",
doi = "10.18632/oncotarget.16837",
language = "English (US)",
volume = "8",
pages = "39230--39240",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "24",

}

TY - JOUR

T1 - Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells

AU - An, Jun

AU - Xue, Ying

AU - Long, Meijun

AU - Zhang, Ge

AU - Zhang, Junhang

AU - Su, Hang

PY - 2017

Y1 - 2017

N2 - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cancer killer in the world. Despite the recent advances in its diagnosis and therapy, the prognosis of NSCLC patients remains very poor, mainly due to the development of drug resistance and metastasis. Both the chemokine network and the matrix metalloproteinase (MMP) system play important roles in cancer cell metastasis. The disruption of CCL2/CCR2 chemokine signaling has been shown to suppress cancer cellviability and metastasis. CCL2-neutralizing antibodies, which have shown promising therapeutic efficacy in several cancer models, are not widely used due to technical issues. CCR2 antagonism has thus become an alternative method for cancer treatment. However, the effect of CCR2 antagonists on NSCLC progression remains poorly understood. Here, we investigated the effect of CCR2 antagonist (CAS445479-97-0) on the proliferation, migration and invasion of human lung adenocarcinoma A549 cells by using WST-1 cell viability assay, transwell migration assay, wound healing scratch assay and Matrigel invasion assay. We demonstrated that CCL2 treatment promoted A549 cell viability, motility and invasion by upregulating MMP-9 expression and that this induction was significantly suppressed by CAS 445479-97-0. Taken together, our data suggested that the CCR2 antagonist would be a potential drug for treating CCR2-positive NSCLC patients.

AB - Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cancer killer in the world. Despite the recent advances in its diagnosis and therapy, the prognosis of NSCLC patients remains very poor, mainly due to the development of drug resistance and metastasis. Both the chemokine network and the matrix metalloproteinase (MMP) system play important roles in cancer cell metastasis. The disruption of CCL2/CCR2 chemokine signaling has been shown to suppress cancer cellviability and metastasis. CCL2-neutralizing antibodies, which have shown promising therapeutic efficacy in several cancer models, are not widely used due to technical issues. CCR2 antagonism has thus become an alternative method for cancer treatment. However, the effect of CCR2 antagonists on NSCLC progression remains poorly understood. Here, we investigated the effect of CCR2 antagonist (CAS445479-97-0) on the proliferation, migration and invasion of human lung adenocarcinoma A549 cells by using WST-1 cell viability assay, transwell migration assay, wound healing scratch assay and Matrigel invasion assay. We demonstrated that CCL2 treatment promoted A549 cell viability, motility and invasion by upregulating MMP-9 expression and that this induction was significantly suppressed by CAS 445479-97-0. Taken together, our data suggested that the CCR2 antagonist would be a potential drug for treating CCR2-positive NSCLC patients.

KW - CCR2 antagonist

KW - MMP-9

KW - Motility and invasion

KW - Non-small cell lung cancer

KW - Viability

UR - http://www.scopus.com/inward/record.url?scp=85020658949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020658949&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16837

DO - 10.18632/oncotarget.16837

M3 - Article

VL - 8

SP - 39230

EP - 39240

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -